Sepsis Diagnostics Market: Information by Product (Instruments), Technology (Microbiology), Pathogen (Bacterial Sepsis), Testing Type (Laboratory Testing), and Region — Forecast till 2029

Dec 08, 2020   Market Overview Sepsis is a type of life-threatening organ failure arising when the body's reaction to an infection injures its tissues and organs. It may be caused by chronic infections, kidney or liver inflammation, tumors, serious injuries, and a weak immune system. Sepsis occurs in two forms; extreme sepsis and septic shock, with severe sepsis cases causing decreased blood pressure. Hospital-acquired infections and the increasing incidence of sepsis have contributed to a growing need for ea...
Request Free Sample Report

Report Description

Market Overview

Sepsis is a type of life-threatening organ failure arising when the body's reaction to an infection injures its tissues and organs. It may be caused by chronic infections, kidney or liver inflammation, tumors, serious injuries, and a weak immune system. Sepsis occurs in two forms; extreme sepsis and septic shock, with severe sepsis cases causing decreased blood pressure. Hospital-acquired infections and the increasing incidence of sepsis have contributed to a growing need for early intervention, one of the driving forces in demand for diagnostic sepsis.

The global sepsis diagnostics market was estimated at USD 426 million in 2019 and is expected to grow at 8.4% CAGR during the forecast study period.

Sepsis-Diagnostics-Market

Market Drivers

High Prevalence of Sepsis Coupled with the Mounting Burden of Hospital-Acquired Infections (HAIs)

The latest findings have shown that this life-threatening illness is rapidly widespread across the globe. Sepsis usually impacts more than 30 million people globally and contributes to about 6 million deaths per year, according to reports released by WHO in April 2018. The same report reports that almost 3 million new-born and 1.2 million children worldwide suffer from this disease every year. Such a high prevalence of sepsis will an increase in demand for diagnostic solutions and fuel market growth.

Besides, hospital-acquired infections (HAIs) can trigger sepsis, particularly in geriatric populations, new-born babies, and chronic disease sufferers. According to CDC estimates, about 1.7 million patients suffer from HAIs every year, and about 99,000 patients die from HAIs in the United States.

In the UHAIs were ranked in the top five leading causes of death. Surgical infections, pulmonary infections, urinary tract infections, and bloodstream infections include some of the most frequent hospital-acquired infection forms. Post-surgery bloodstream infections have been augmented by 8%, while urinary tract infections by 3.6%, as per the American Hospital Association, owing to catheter use during surgery.

Sepsis-Diagnostics-Market-Growth

The similar status of hospital-acquired infections has been observed globally and raises the need for diagnosis of sepsis. Therefore, the increase in hospital-acquired infections is projected to fuel the sepsis diagnosis industry's overall growth over the projected period.

High Demand for Rapid Diagnostic Tests, Increasing Regulatory Coupled with Rising Government Initiatives

Most of the current sepsis diagnostic tests will take up to 72 hours to process and deliver final results. Therefore, there is a strong demand for fast diagnostic testing on the market to detect this life-threatening disease, saving thousands of lives. A cost-effective procedure for early detection of sepsis was found by researchers at Strathclyde University in February 2019.

This recently designed procedure uses a microelectrode to evaluate patients' blood, and in only two and a half minutes, it can produce final tests. Key market players have lucrative opportunities to strengthen their market position by developing and launching such innovative rapid tests.

In May 2018. T2 Biosystems, Inc., a U.S.-based emerging medical research technologies firm, obtained FDA clearance for its T2Bacteria Panel for the identification of human whole blood specimens of particular sepsis-causing bacterial pathogens. In April 2019, a Scotland-wide program to promote public awareness about the signs and effects of sepsis, initiated by the Scottish Government in partnership with Sepsis Science. Such public awareness-raising campaigns are projected to boost the need for accelerated medical examination technologies and help market growth in the coming years.

Market Segmentation

Bacterial Sepsis to Dominate the Pathogen Segment

The bacterial sepsis segment held the largest market share in 2019 and is anticipated to maintain its supremacy over the projected period, primarily owing to its high prevalence. According to the report released by SAGE Journals in January 2019, bacterial sepsis is the most prevalent type, with 62.2% of patients diagnosed with Gram-negative bacteria and 46.8% Gram-positive bacteria.

In the bacterial sepsis field, the Gram-negative bacteria segment is predicted to lead the demand over the projected period. Robust R&D activities and increased regulatory approval of novel solutions are expected to support growth in the segment. GenMark Diagnostics, Inc., for example, obtained the U.S. approval in April 2019. FDA clearance for their new panel test was designed to diagnose sepsis-causing gram-negative bacteria.

Molecular Diagnostics Is Predicted to Be the Fastest-Growing Segment

Sepsis affects significant groups of patients in hospitals and is the sixth most frequent cause for hospitalization. Rapid and precise identification of pathogen-causing pathogens remains a significant problem in contemporary healthcare. Finally, recognizing the causative pathogen as part of the procedure is important in choosing effective antibiotic therapy. Such requirements make the molecular diagnosis (MDx) and desirable method to be considered for sepsis diagnosis. Due to its simple feasibility and precision in the diagnosis processes, molecular diagnostics have gained popularity amongst many international corporations and organizations.

The blood culture study has become the gold standard for the molecular testing process for fast and precise pathogens' characterization. However, as compared to traditional methods, the cost of molecular diagnostics has remained very high. This scenario will create lucrative opportunities for key players to develop cost-effective solutions. For early identification of bacterial and viral infections and improved patient management, numerous companies invest in point-of-care molecular diagnostics.

This segment's development is projected to be driven by a well-established healthcare system with fast penetration of innovative medical technology coupled with the increasing importance of early disease detection.

Regional Overview

The regional analysis has been made considering the trends of the sepsis diagnostics market, in the regions of North America, Europe, Asia-Pacific, South America, the Middle East, and Africa.

North-America-Sepsis-Diagnostics-Market

North America Dominated the Global Sepsis Diagnostics Market

North America held a dominant revenue position in 2019 and is expected to maintain its dominance over the forecast period. Sepsis affects more than a million Americans each year, according to the CDC estimates in 2018, contributing to 15%-30% casualties in the United States. Besides, due to an increase in the geriatric population, diseases that are incurable with antibiotics, and higher risks of disease among people who have undergone organ transplantation, the number of sepsis cases are growing yearly in the world.

Furthermore, numerous trials based on sepsis are funded by the National Institutes of Health that aids in testing different possible therapies for the condition. The 'Stay Ahead of Sepsis,' an educational campaign initiated by the CDC to shield Americans from the impact of sepsis. This program calls for healthcare providers to advise patients early, avoid infections, detect and diagnose sepsis, and immediately initiate sepsis treatment.

Emerging technology linked to an improved understanding of the neonatal immune system's developing responses to early infection offers an opportunity to establish biomarkers to boost early detection. Thus, the growing prevalence of sepsis and government initiatives will increase the studied sector's growth in this region.

Asia-Pacific Anticipated to Show Promising Growth during the Forecast Period

 Asia-Pacific sepsis diagnostics market will experience promising growth over the forecast period. The key players competing on the market are implementing organic growth approaches, such as product creation and launching, to achieve substantial business share. For, e.g., Sysmex Corporation, based in Japan, released its latest HISCL Presepsin Assay Package in August 2018.

This kit is intended to calculate the presepsin levels, an important test parameter for bacterial sepsis. Also, the high prevalence of sepsis is projected to fuel demand for its diagnostic solutions in key Asia-Pacific countries. According to a study released by PLOS Journal, clinical sepsis affected around 17,000 out of 100,000 live births in India.

Furthermore, rising neonatal umbilical cord sepsis cases in India, Pakistan, and China generate major opportunities in APAC’s demand for sepsis diagnosis. According to a survey by Mullany et al., Nepal reported a 16% incidence of cord infection, also about 6%.

Key Players

  • Abbott
  • Beckman Coulter, Inc.
  • Becton, Dickinson, and Company
  • BioMérieux SA
  • Bruker Corporation
  • Cepheid Inc.
  • Hoffmann-La Roche AG
  • Nanosphere, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Recent Developments

  • In December 2019, U.S.-based Ontera, Inc. and England-based QuantuMDx Group Limited strategically partnered for the development of advanced sepsis diagnostic solutions.
  • In September 2019, T2 Biosystems entered into an agreement with BioNuclear Puerto Rico to expand its distribution of rapid diagnostic technologies, including the T2Bacteria and T2Candida Panels, in Puerto Rico and the US Virgin Islands.
  • In December 2018, BioMérieux obtained FDA clearance for the use of BPA and BPN with BACT / ALERT VIRTUO for quality control testing of platelets.
  • In November 2018, BioMérieux received FDA and CE approval for BIOFIRE FILMARRAY Pneumonia Panels.

Sepsis Diagnostics Market: Segmentation

By Product

  • Instruments
  • Blood culture media
  • Assay kits and reagents
  • Software

By Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry

By Pathogen

  • Bacterial Sepsis
  • Fungal Sepsis
  • Others

By Testing Type

  • Laboratory Testing
  • PoC Testing

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • Central and South America and the Caribbean
  • The Middle-East and Africa

Frequently Asked Questions (FAQs)

The global sepsis diagnostics market was estimated at USD 426 million in 2019 and is expected to grow at 8.4% CAGR during the forecast study period.
The increasing incidence of sepsis has contributed to a growing need for early intervention, increasing regulations coupled with rising government initiatives are the key factors expected to drive Sepsis Diagnostics Market during the forecast period.
North America is expected to hold the highest market share in Sepsis Diagnostics Market.
Abbott, Beckman Coulter, Inc., Becton, Dickinson, and Company, BioMérieux SA, Bruker Corporation, Cepheid Inc., F. Hoffmann-La Roche AG, Nanosphere Inc., Sysmex Corporation are the top players in Sepsis Diagnostics Market.
In 2019 Global Sepsis Diagnostics Market was valued at USD 426 million.
Bacterial Sepsis Segment is expected to be the leading segment in Sepsis Diagnostics Market during the forecast period.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically, choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.

Market Overview

Sepsis is a type of life-threatening organ failure arising when the body's reaction to an infection injures its tissues and organs. It may be caused by chronic infections, kidney or liver inflammation, tumors, serious injuries, and a weak immune system. Sepsis occurs in two forms; extreme sepsis and septic shock, with severe sepsis cases causing decreased blood pressure. Hospital-acquired infections and the increasing incidence of sepsis have contributed to a growing need for early intervention, one of the driving forces in demand for diagnostic sepsis.

The global sepsis diagnostics market was estimated at USD 426 million in 2019 and is expected to grow at 8.4% CAGR during the forecast study period.

Sepsis-Diagnostics-Market

Market Drivers

High Prevalence of Sepsis Coupled with the Mounting Burden of Hospital-Acquired Infections (HAIs)

The latest findings have shown that this life-threatening illness is rapidly widespread across the globe. Sepsis usually impacts more than 30 million people globally and contributes to about 6 million deaths per year, according to reports released by WHO in April 2018. The same report reports that almost 3 million new-born and 1.2 million children worldwide suffer from this disease every year. Such a high prevalence of sepsis will an increase in demand for diagnostic solutions and fuel market growth.

Besides, hospital-acquired infections (HAIs) can trigger sepsis, particularly in geriatric populations, new-born babies, and chronic disease sufferers. According to CDC estimates, about 1.7 million patients suffer from HAIs every year, and about 99,000 patients die from HAIs in the United States.

In the UHAIs were ranked in the top five leading causes of death. Surgical infections, pulmonary infections, urinary tract infections, and bloodstream infections include some of the most frequent hospital-acquired infection forms. Post-surgery bloodstream infections have been augmented by 8%, while urinary tract infections by 3.6%, as per the American Hospital Association, owing to catheter use during surgery.

Sepsis-Diagnostics-Market-Growth

The similar status of hospital-acquired infections has been observed globally and raises the need for diagnosis of sepsis. Therefore, the increase in hospital-acquired infections is projected to fuel the sepsis diagnosis industry's overall growth over the projected period.

High Demand for Rapid Diagnostic Tests, Increasing Regulatory Coupled with Rising Government Initiatives

Most of the current sepsis diagnostic tests will take up to 72 hours to process and deliver final results. Therefore, there is a strong demand for fast diagnostic testing on the market to detect this life-threatening disease, saving thousands of lives. A cost-effective procedure for early detection of sepsis was found by researchers at Strathclyde University in February 2019.

This recently designed procedure uses a microelectrode to evaluate patients' blood, and in only two and a half minutes, it can produce final tests. Key market players have lucrative opportunities to strengthen their market position by developing and launching such innovative rapid tests.

In May 2018. T2 Biosystems, Inc., a U.S.-based emerging medical research technologies firm, obtained FDA clearance for its T2Bacteria Panel for the identification of human whole blood specimens of particular sepsis-causing bacterial pathogens. In April 2019, a Scotland-wide program to promote public awareness about the signs and effects of sepsis, initiated by the Scottish Government in partnership with Sepsis Science. Such public awareness-raising campaigns are projected to boost the need for accelerated medical examination technologies and help market growth in the coming years.

Market Segmentation

Bacterial Sepsis to Dominate the Pathogen Segment

The bacterial sepsis segment held the largest market share in 2019 and is anticipated to maintain its supremacy over the projected period, primarily owing to its high prevalence. According to the report released by SAGE Journals in January 2019, bacterial sepsis is the most prevalent type, with 62.2% of patients diagnosed with Gram-negative bacteria and 46.8% Gram-positive bacteria.

In the bacterial sepsis field, the Gram-negative bacteria segment is predicted to lead the demand over the projected period. Robust R&D activities and increased regulatory approval of novel solutions are expected to support growth in the segment. GenMark Diagnostics, Inc., for example, obtained the U.S. approval in April 2019. FDA clearance for their new panel test was designed to diagnose sepsis-causing gram-negative bacteria.

Molecular Diagnostics Is Predicted to Be the Fastest-Growing Segment

Sepsis affects significant groups of patients in hospitals and is the sixth most frequent cause for hospitalization. Rapid and precise identification of pathogen-causing pathogens remains a significant problem in contemporary healthcare. Finally, recognizing the causative pathogen as part of the procedure is important in choosing effective antibiotic therapy. Such requirements make the molecular diagnosis (MDx) and desirable method to be considered for sepsis diagnosis. Due to its simple feasibility and precision in the diagnosis processes, molecular diagnostics have gained popularity amongst many international corporations and organizations.

The blood culture study has become the gold standard for the molecular testing process for fast and precise pathogens' characterization. However, as compared to traditional methods, the cost of molecular diagnostics has remained very high. This scenario will create lucrative opportunities for key players to develop cost-effective solutions. For early identification of bacterial and viral infections and improved patient management, numerous companies invest in point-of-care molecular diagnostics.

This segment's development is projected to be driven by a well-established healthcare system with fast penetration of innovative medical technology coupled with the increasing importance of early disease detection.

Regional Overview

The regional analysis has been made considering the trends of the sepsis diagnostics market, in the regions of North America, Europe, Asia-Pacific, South America, the Middle East, and Africa.

North-America-Sepsis-Diagnostics-Market

North America Dominated the Global Sepsis Diagnostics Market

North America held a dominant revenue position in 2019 and is expected to maintain its dominance over the forecast period. Sepsis affects more than a million Americans each year, according to the CDC estimates in 2018, contributing to 15%-30% casualties in the United States. Besides, due to an increase in the geriatric population, diseases that are incurable with antibiotics, and higher risks of disease among people who have undergone organ transplantation, the number of sepsis cases are growing yearly in the world.

Furthermore, numerous trials based on sepsis are funded by the National Institutes of Health that aids in testing different possible therapies for the condition. The 'Stay Ahead of Sepsis,' an educational campaign initiated by the CDC to shield Americans from the impact of sepsis. This program calls for healthcare providers to advise patients early, avoid infections, detect and diagnose sepsis, and immediately initiate sepsis treatment.

Emerging technology linked to an improved understanding of the neonatal immune system's developing responses to early infection offers an opportunity to establish biomarkers to boost early detection. Thus, the growing prevalence of sepsis and government initiatives will increase the studied sector's growth in this region.

Asia-Pacific Anticipated to Show Promising Growth during the Forecast Period

 Asia-Pacific sepsis diagnostics market will experience promising growth over the forecast period. The key players competing on the market are implementing organic growth approaches, such as product creation and launching, to achieve substantial business share. For, e.g., Sysmex Corporation, based in Japan, released its latest HISCL Presepsin Assay Package in August 2018.

This kit is intended to calculate the presepsin levels, an important test parameter for bacterial sepsis. Also, the high prevalence of sepsis is projected to fuel demand for its diagnostic solutions in key Asia-Pacific countries. According to a study released by PLOS Journal, clinical sepsis affected around 17,000 out of 100,000 live births in India.

Furthermore, rising neonatal umbilical cord sepsis cases in India, Pakistan, and China generate major opportunities in APAC’s demand for sepsis diagnosis. According to a survey by Mullany et al., Nepal reported a 16% incidence of cord infection, also about 6%.

Key Players

  • Abbott
  • Beckman Coulter, Inc.
  • Becton, Dickinson, and Company
  • BioMérieux SA
  • Bruker Corporation
  • Cepheid Inc.
  • Hoffmann-La Roche AG
  • Nanosphere, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Recent Developments

  • In December 2019, U.S.-based Ontera, Inc. and England-based QuantuMDx Group Limited strategically partnered for the development of advanced sepsis diagnostic solutions.
  • In September 2019, T2 Biosystems entered into an agreement with BioNuclear Puerto Rico to expand its distribution of rapid diagnostic technologies, including the T2Bacteria and T2Candida Panels, in Puerto Rico and the US Virgin Islands.
  • In December 2018, BioMérieux obtained FDA clearance for the use of BPA and BPN with BACT / ALERT VIRTUO for quality control testing of platelets.
  • In November 2018, BioMérieux received FDA and CE approval for BIOFIRE FILMARRAY Pneumonia Panels.

Sepsis Diagnostics Market: Segmentation

By Product

  • Instruments
  • Blood culture media
  • Assay kits and reagents
  • Software

By Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry

By Pathogen

  • Bacterial Sepsis
  • Fungal Sepsis
  • Others

By Testing Type

  • Laboratory Testing
  • PoC Testing

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • Central and South America and the Caribbean
  • The Middle-East and Africa

Frequently Asked Questions (FAQs)

The global sepsis diagnostics market was estimated at USD 426 million in 2019 and is expected to grow at 8.4% CAGR during the forecast study period.
The increasing incidence of sepsis has contributed to a growing need for early intervention, increasing regulations coupled with rising government initiatives are the key factors expected to drive Sepsis Diagnostics Market during the forecast period.
North America is expected to hold the highest market share in Sepsis Diagnostics Market.
Abbott, Beckman Coulter, Inc., Becton, Dickinson, and Company, BioMérieux SA, Bruker Corporation, Cepheid Inc., F. Hoffmann-La Roche AG, Nanosphere Inc., Sysmex Corporation are the top players in Sepsis Diagnostics Market.
In 2019 Global Sepsis Diagnostics Market was valued at USD 426 million.
Bacterial Sepsis Segment is expected to be the leading segment in Sepsis Diagnostics Market during the forecast period.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically, choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.